Copart Inc
12 nominees · 3 ballot items.
Copart, Inc. shareholder meeting will consider three proposals: election of twelve directors, advisory vote on executive compensation, and ratification of Ernst & Young LLP as the independent auditor for 2026.
Follow how the vote landed and what changed on Copart Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElection of twelve director nominees to hold office until the 2026 annual meeting of stockholders or until their successors are elected and qualified.
- 2
Advisory Vote on Approval of Executive Compensation
ManagementBoard: FORAdvisory (non-binding) vote to approve Copart, Inc.'s named executive officers' compensation for the fiscal year ended July 31, 2025.
- 3
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatification of Ernst & Young LLP as Copart's independent registered public accounting firm for the fiscal year ending July 31, 2026.
Nominees on the ballot12
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.2% | 57,275,216 | $1.9B |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5% | 41,399,089 | $1.4B |
| 3 | STATE STREET CORP | 4.1% | 38,136,070 | $1.3B |
| 4 | Invesco Ltd. | 3.3% | 30,724,832 | $1.0B |
| 5 | PRINCIPAL FINANCIAL GROUP INC | 3.2% | 29,954,919 | $995M |
| 6 | BlackRock, Inc. | 2.5% | 23,052,090 | $765M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 21,441,487 | $709M |
| 8 | BlackRock, Inc. | 2.0% | 18,737,251 | $622M |
| 9 | Capital World Investors | 2.0% | 18,186,568 | $604M |
| 10 | Bank of New York Mellon Corp | 1.3% | 12,044,995 | $400M |
Other Industrials sector meetings6
Upcoming shareholder meetings at Copart Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Copart Inc 2025 annual meeting?
- Copart Inc (CPRT) holds its 2025 annual shareholder meeting on Friday, December 5, 2025.
- What is the record date for the Copart Inc 2025 meeting?
- The record date for the Copart Inc 2025 meeting is Friday, October 10, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Copart Inc's 2025 meeting?
- The board is presenting 12 director nominees at the Copart Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Copart Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Copart Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.